Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Walls

Vascular Surgery Savannah, GA Medical Doctor

NPI 1790721546 CMS profile 869517

4750 Waters Ave, Suite 500, Savannah, GA 31404

Open in the dashboard

General payments

$23,995

147 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Walls of Savannah, GA is reported in the CMS Open Payments database as having received $23,995 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,126 18
2024 General $11,154 40
2023 General $6,538 16
2022 General $552 15
2021 General $540 16
2020 General $1,983 20
2019 General $2,101 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Walls
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Christopher Walls were reported at $1,126. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Christopher Walls Vascular Surgery median Middle half National median
2019 $2,101 $796 $226–$2,363 $163
2020 $1,983 $348 $118–$1,110 $114
2021 $540 $471 $158–$1,421 $132
2022 $552 $725 $222–$2,183 $149
2023 $6,538 $836 $257–$2,440 $160
2024 $11,154 $909 $252–$2,619 $164
2025 $1,126 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $15,432 23 payments
  2. Ge Healthcare $1,862 9 payments
  3. W. L. Gore & Associates, Inc. $1,662 14 payments
  4. Silk Road Medical, Inc. $1,095 5 payments
  5. Cook Medical LLC $558 15 payments
  6. Endologix, Inc. $522 6 payments
  7. Medtronic, Inc. $394 6 payments
  8. Penumbra, Inc. $392 2 payments
  9. CVRx, Inc. $374 8 payments
  10. Medtronic Vascular, Inc. $342 9 payments
  11. Other $1,362 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $14,990 6 payments
  2. Food and Beverage $6,326 135 payments
  3. Travel and Lodging $2,680 6 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $14,990 6 payments
  2. ENROUTE 0.014 Guidewire $832 3 payments
  3. ENROUTE Transcarotid Stent System $832 3 payments
  4. ENROUTE Transcarotid Neuroprotection System $832 3 payments
  5. ENHANCE Transcarotid Peripheral Access Kit $832 3 payments
  6. GORE VIABAHN VBX Balloon Expandable Endo $609 5 payments
  7. AURYON LASER SYSTEM 100-120 VAC Pad $403 16 payments
  8. Indigo $392 2 payments
  9. Barostim Neo System $374 8 payments
  10. AFX2 Bifurcated Endograft System $299 4 payments
  11. Other $5,170 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

123

Median for Vascular Surgery: 122

Drug cost

$11,341

Median for Vascular Surgery: $14,135

Branded share of claims

63.4%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 20 $10,940
Clopidogrel Clopidogrel Bisulfate Brand 30 $138
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 28 $106
Oxycodone Hcl Generic 16 $65
Atorvastatin Calcium Generic 11 $54
Tramadol Hcl Generic 18 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 130 billing codes

Paid by Medicare

$178,095

Of which drugs: $969

Medicare patients

264

Average age 74

Services billed

4,318

119 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 55%
Arthritis 50%
Diabetes 48%
Ischemic heart disease 45%
Heart failure 36%
Depression 28%
Atrial fibrillation 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 24 3,202 $928
Injection, fentanyl citrate, 0.1 mg J3010 Office 22 27 $20
Injection, midazolam hydrochloride, per 1 mg J2250 Office 21 50 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record